Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | CDK9 inhibition with voruciclib for treating AML and R/R B-cell NHL

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, introduces a Phase I dose-escalation study (NCT03547115) of the oral CDK9 inhibitor (CDK9i) voruciclib in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML). The preliminary results demonstrate promising efficacy and tolerability, with no significant myelosuppression or dose-limiting toxicities (DLTs). The trial is now evaluating voruciclib in combination with venetoclax. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consultancy: Research to Practice, Mingsight Pharmaceuticals, Merck, Janssen, Genentech, Eli Lilly, Curio Science, BMS, BeiGene, Aptitude Health, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, Secura Bio, TG Therapeutics, Takeda, ONO Pharmaceuticals, AbbVie
Research Funding: Genentech, Ascentage Pharma, AstraZeneca, Surface Oncology, Novartis, TG Therapeutics, MEI Pharma, AbbVie